Vericel Anticipates Strong Second Half for MACI

Vericel reported 2Q22 orthopedic sales of $28.6 million, +7.9% vs. 2Q21. The company generated the highest MACI revenue total of any non-4Q since launch.

The company beat a difficult prior-year comparison for MACI and expects a larger than typical step up in the third quarter with about 20% year-over-year growth. Vericel expects MACI...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us